FFM

Fairmount Funds Management Portfolio holdings

AUM $1.11B
1-Year Est. Return 120.99%
This Quarter Est. Return
1 Year Est. Return
+120.99%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.11B
AUM Growth
+$340M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
18
New
Increased
Reduced
Closed

Top Buys

1
+$60.6M
2
+$39.9M
3
+$23.6M
4
ORKA
Oruka Therapeutics
ORKA
+$6.41M

Top Sells

1
+$8.85M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$1.81B
$130M 11.71%
3,307,191
+600,000
COGT icon
2
Cogent Biosciences
COGT
$5.98B
$129M 11.63%
9,003,418
+2,777,777
AXSM icon
3
Axsome Therapeutics
AXSM
$7.16B
$99M 8.91%
815,176
APGE icon
4
Apogee Therapeutics
APGE
$4.72B
$81.4M 7.32%
2,048,647
ELVN icon
5
Enliven Therapeutics
ELVN
$1.22B
$76M 6.84%
3,711,444
VRDN icon
6
Viridian Therapeutics
VRDN
$2.9B
$74.7M 6.72%
3,459,913
ORKA
7
Oruka Therapeutics
ORKA
$1.35B
$71.3M 6.41%
3,705,262
+333,340
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$3.04B
$68.8M 6.19%
1,772,839
SRRK icon
9
Scholar Rock
SRRK
$4.19B
$67.9M 6.11%
1,824,031
SYRE icon
10
Spyre Therapeutics
SYRE
$2.2B
$67.3M 6.06%
4,018,101
NUVL icon
11
Nuvalent
NUVL
$8.15B
$62.9M 5.66%
727,563
ABVX
12
Abivax
ABVX
$8.95B
$60.6M 5.45%
+713,434
ZBIO
13
Zenas BioPharma
ZBIO
$1.85B
$42M 3.78%
1,892,806
JBIO
14
Jade Biosciences
JBIO
$535M
$27.8M 2.5%
3,220,368
ATXS icon
15
Astria Therapeutics
ATXS
$719M
$25.9M 2.33%
3,554,129
CBIO
16
Crescent Biopharma
CBIO
$220M
$16.5M 1.48%
1,387,866
IKT icon
17
Inhibikase Therapeutics
IKT
$171M
$9.92M 0.89%
6,125,000
CTMX icon
18
CytomX Therapeutics
CTMX
$646M
– –
-3,896,582